Laura Catena

1.5k total citations
48 papers, 1.0k citations indexed

About

Laura Catena is a scholar working on Oncology, Epidemiology and Neurology. According to data from OpenAlex, Laura Catena has authored 48 papers receiving a total of 1.0k indexed citations (citations by other indexed papers that have themselves been cited), including 32 papers in Oncology, 25 papers in Epidemiology and 17 papers in Neurology. Recurrent topics in Laura Catena's work include Neuroendocrine Tumor Research Advances (25 papers), Lung Cancer Research Studies (18 papers) and Neuroblastoma Research and Treatments (16 papers). Laura Catena is often cited by papers focused on Neuroendocrine Tumor Research Advances (25 papers), Lung Cancer Research Studies (18 papers) and Neuroblastoma Research and Treatments (16 papers). Laura Catena collaborates with scholars based in Italy, United States and Malaysia. Laura Catena's co-authors include Emilio Bajetta, Giuseppe Procopio, Roberto Buzzoni, Antonia Martinetti, Sara De Dosso, Leonardo Ferrari, S. Della Torre, Marco Platania, E. Bichisao and Luigi Celio and has published in prestigious journals such as Journal of Clinical Oncology, Cancer and Radiology.

In The Last Decade

Laura Catena

44 papers receiving 974 citations

Peers

Laura Catena

ONCOL

EPIDE

NEURO

PRM

Hidefumi Inaba Japan

Luisa Losi Italy

Dianrong Xiu China

Piero Ferollà Italy

S Garancini Italy

Ying Kan China

María Apellániz-Ruiz Spain

Tomoki Utsumi Japan

M. Wied Germany

Junhong Li China

Hidefumi Inaba Japan

Laura Catena

316 ×0.4

ONCOL

282 ×0.4

EPIDE

135 ×0.3

NEURO

66 ×0.7

PRM

109 ×1.1

Citations per year, relative to Laura Catena Laura Catena (= 1×) peers Hidefumi Inaba

Countries citing papers authored by Laura Catena

Since Specialization

Citations

This map shows the geographic impact of Laura Catena's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Laura Catena with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Laura Catena more than expected).

Fields of papers citing papers by Laura Catena

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Laura Catena. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Laura Catena. The network helps show where Laura Catena may publish in the future.

Co-authorship network of co-authors of Laura Catena

This figure shows the co-authorship network connecting the top 25 collaborators of Laura Catena. A scholar is included among the top collaborators of Laura Catena based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Laura Catena. Laura Catena is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Marcon, Ilaria, et al.. (2023). Real-World Evaluation of the Management, Treatment Pathways and Outcome of Melanoma Patients with Target Therapies in Italy. Advances in Therapy. 40(9). 3875–3895. 2 indexed citations

Bajetta, Emilio, Laura Catena, Sara Pusceddu, et al.. (2017). Everolimus in Combination with Octreotide Long-Acting Repeatable in a First-Line Setting for Patients with Neuroendocrine Tumors: A 5-Year Update. Neuroendocrinology. 106(4). 307–311. 16 indexed citations

Bajetta, Emilio, Laura Catena, Nicola Fazio, et al.. (2014). Everolimus in combination with octreotide long‐acting repeatable in a first‐line setting for patients with neuroendocrine tumors: An ITMO group study. Cancer. 120(16). 2457–2463. 56 indexed citations

Catena, Laura, et al.. (2013). El concepto de formación socio-económica en la obra de José María Aricó: Un cotejo con las fuentes marxianas. Izquierdas. 93–105. 1 indexed citations

Bajetta, Emilio, Laura Catena, Nicola Fazio, et al.. (2013). Everolimus in combination with octreotide LAR as the first-line treatment for advanced neuroendocrine tumors: A phase II trial of the I.T.M.O. (Italian Trials in Medical Oncology) group.. Journal of Clinical Oncology. 31(15_suppl). 4136–4136. 4 indexed citations

Catena, Laura, Emilio Bajetta, Massimo Milione, et al.. (2011). Mammalian target of rapamycin expression in poorly differentiated endocrine carcinoma: clinical and therapeutic future challenges. Targeted Oncology. 6(2). 65–68. 34 indexed citations

Valente, Monica, Laura Catena, Massimo Milione, et al.. (2010). Common Diagnostic Challenges in the Histopathologic Diagnosis of Neuroendocrine Lung Tumors: A Case Report. Case Reports in Oncology. 3(2). 202–207. 6 indexed citations

Fagnani, Daniele, Alessandro Bertolini, Laura Catena, et al.. (2008). The impact of antithrombotic prophylaxis on infectious complications in cancer patients with central venous catheters: an observational study. Blood Coagulation & Fibrinolysis. 20(1). 35–40. 3 indexed citations

Bajetta, Emilio, Marco Platania, Laura Catena, et al.. (2007). MERKEL CELL CARCINOMAAFTER LIVER TRANSPLANTATION: A CASE REPORT. Tumori. 97(3). 323–326. 1 indexed citations

10.

Procopio, Giuseppe, Elena Verzoni, Arpine Gevorgyan, et al.. (2007). Safety and Activity of Sorafenib in Different Histotypes of Advanced Renal Cell Carcinoma. Oncology. 73(3-4). 204–209. 20 indexed citations

11.

Dosso, Sara De, Emilio Bajetta, Giuseppe Procopio, et al.. (2007). Pulmonary Carcinoid Tumours: Indolent but Not Benign. Oncology. 73(3-4). 162–168. 18 indexed citations

12.

Bajetta, Emilio, Laura Catena, Giuseppe Procopio, et al.. (2006). Are capecitabine and oxaliplatin (XELOX) suitable treatments for progressing low-grade and high-grade neuroendocrine tumours?. Cancer Chemotherapy and Pharmacology. 59(5). 637–642. 171 indexed citations

13.

Bajetta, Emilio, Giuseppe Procopio, Laura Catena, et al.. (2006). Lanreotide autogel every 6 weeks compared with Lanreotide microparticles every 3 weeks in patients with well differentiated neuroendocrine tumors. Cancer. 107(10). 2474–2481. 60 indexed citations

14.

Bajetta, Emilio, Laura Catena, Giuseppe Procopio, et al.. (2005). Is the new WHO classification of neuroendocrine tumours useful for selecting an appropriate treatment?. Annals of Oncology. 16(8). 1374–1380. 57 indexed citations

15.

Bajetta, Emilio, Giuseppe Procopio, Leonardo Ferrari, et al.. (2003). Update on the treatment of neuroendocrine tumors. Expert Review of Anticancer Therapy. 3(5). 631–642. 19 indexed citations

16.

Bajetta, Emilio, L. Ferrari, Giuseppe Procopio, et al.. (2002). Efficacy of a chemotherapy combination for the treatment of metastatic neuroendocrine tumours. Annals of Oncology. 13(4). 614–621. 88 indexed citations

17.

Ferrari, L., Antonia Martinetti, Nicoletta Zilembo, et al.. (2002). Short-term effects of anastrozole treatment on insulin-like growth factor system in postmenopausal advanced breast cancer patients. The Journal of Steroid Biochemistry and Molecular Biology. 80(4-5). 411–418. 10 indexed citations

18.

Bajetta, Emilio, Giuseppe Procopio, Leonardo Ferrari, et al.. (2002). A randomized, multicenter prospective trial assessing long‐acting release octreotide pamoate plus tamoxifen as a first line therapy for advanced breast carcinoma. Cancer. 94(2). 299–304. 30 indexed citations

19.

Bajetta, Emilio, et al.. (2001). Advances in diagnosis and therapy of neuroendocrine tumors. Expert Review of Anticancer Therapy. 1(3). 371–381. 6 indexed citations

20.

Sivit, C J, et al.. (1991). Sonography in neonatal congenital adrenal hyperplasia.. American Journal of Roentgenology. 156(1). 141–143. 32 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact